{"id":7013,"date":"2025-05-22T13:10:50","date_gmt":"2025-05-22T10:10:50","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7013"},"modified":"2025-05-22T13:10:50","modified_gmt":"2025-05-22T10:10:50","slug":"article-summary-title-tirzepatide-tops-semaglutide-for-weight-loss","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/article-summary-title-tirzepatide-tops-semaglutide-for-weight-loss\/","title":{"rendered":"Article summary :Title: Tirzepatide Tops Semaglutide for Weight Loss"},"content":{"rendered":"
Article summary :Title: Tirzepatide Tops Semaglutide for Weight Loss<\/div>\n
Author: Becky McCall, MSc, MScPH<\/div>\n
Published: May 12, 2025<\/div>\n
Source: Medscape<\/div>\n
<\/div>\n
Key Summary Points<\/div>\n
<\/div>\n
1. Study Background \u2013 SURMOUNT-5 Trial<\/div>\n
\u2022 First direct head-to-head trial comparing tirzepatide vs semaglutide in patients with obesity but without type 2 diabetes.<\/span><\/div>\n
\u2022 Conducted over 72 weeks, presented at ECO 2025, and published in NEJM.<\/span><\/div>\n
\u2022 Sponsored by Eli Lilly, the maker of tirzepatide (Mounjaro\/Zepbound).<\/span><\/div>\n
<\/div>\n
2. Participants and Design<\/div>\n
\u2022 751 adults (mean BMI: 39.4; mean weight: 113 kg) randomized:<\/span><\/div>\n
\u2022 Tirzepatide group: 10 or 15 mg weekly (n = 374)<\/span><\/div>\n
\u2022 Semaglutide group: 1.7 or 2.4 mg weekly (n = 376)<\/span><\/div>\n
\u2022 Mean age: 44.7 years; 65% women; 76% White<\/span><\/div>\n
\u2022 Median duration of obesity: 16 years<\/span><\/div>\n
<\/div>\n
3. Primary Outcomes \u2013 Weight Loss<\/div>\n
\u2022 Tirzepatide: \u221220.2% weight loss<\/span><\/div>\n
\u2022 Semaglutide: \u221213.7% weight loss<\/span><\/div>\n
\u2022 P < .001 for superiority of tirzepatide<\/span><\/div>\n
\u2022 Waist circumference reduction: 18.4 cm (tirzepatide) vs 13.0 cm (semaglutide)<\/span><\/div>\n
<\/div>\n
4. Proportion Achieving Weight Loss Targets<\/div>\n
\u2022 \u226510%: 81.6% (tirzepatide) vs 60.5% (semaglutide)<\/span><\/div>\n
\u2022 \u226515%: 64.6% vs 40.1%<\/span><\/div>\n
\u2022 \u226520%: 48.4% vs 27.3%<\/span><\/div>\n
\u2022 \u226525%: 31.6% vs 16.1%<\/span><\/div>\n
<\/div>\n
5. Metabolic Improvements (Greater with Tirzepatide)<\/div>\n
\u2022 Greater reduction in:<\/span><\/div>\n
\u2022 BMI, systolic\/diastolic BP, glycemia, insulin, triglycerides, VLDL<\/span><\/div>\n
\u2022 Greater increase in:<\/span><\/div>\n
\u2022 HDL cholesterol<\/span><\/div>\n
\u2022 Similar reductions in LDL and non-HDL cholesterol in both groups<\/span><\/div>\n
<\/div>\n
6. Safety Profile<\/div>\n
\u2022 GI side effects most common; occurred during dose escalation.<\/span><\/div>\n
\u2022 Treatment-emergent AEs: 76.7% (tirzepatide), 79.0% (semaglutide)<\/span><\/div>\n
\u2022 Serious AEs: 3.5% vs 4.8%<\/span><\/div>\n
\u2022 Discontinuation rates: 6.1% vs 8.0%<\/span><\/div>\n
<\/div>\n
7. Clinical Implications<\/div>\n
\u2022 Tirzepatide outperformed semaglutide in both weight loss and metabolic improvements.<\/span><\/div>\n
\u2022 Choice between the two may depend on availability, guidelines, and healthcare system factors.<\/span><\/div>\n
\u2022 Commentators note that tirzepatide\u2019s dual GIP\/GLP-1 action likely explains superiority.<\/span><\/div>\n
https:\/\/www.medscape.com\/viewarticle\/tirzepatide-tops-semaglutide-weight-loss-2025a1000bdq<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Article summary :Title: Tirzepatide Tops Semaglutide for Weight Loss Author: Becky McCall, MSc, MScPH Published: May 12, 2025 Source: Medscape Key Summary Points 1. Study Background \u2013 SURMOUNT-5 Trial \u2022 First direct head-to-head trial comparing tirzepatide vs semaglutide in patients with obesity but without type 2 diabetes. \u2022 Conducted over 72 weeks, presented at ECO […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7013","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7013"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7013\/revisions"}],"predecessor-version":[{"id":7014,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7013\/revisions\/7014"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}